How much could $10,000 invested in CSL shares be worth next year?

Do analysts think it would be worth sinking money into this top stock?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're fortunate enough to have $10,000 sitting in your savings account and no immediate use for it, then it could be worth putting it to work in the share market.

After all, with a historic return in the region of 10%, that $10,000 could become $11,000 in 12 months if history were to repeat itself.

In addition, if you can find an ASX share with market-beating potential, then you could grow your wealth even more.

But which shares could do this? Could CSL Ltd (ASX: CSL) shares beat the market? Let's find out.

A man thinks very carefully about his money and investments.

Image source: Getty Images

$10,000 invested in CSL shares

At present, the CSL share price is trading at $289.24. This means that if you were to invest $10,000 (and a further $123.40), you would end up owning 35 units.

According to a recent note out of Morgans, its analysts see scope for the company's shares to rise from current levels. The broker said:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Morgans has an add rating and $315.35 price target on CSL's shares. This implies potential upside of 9% and values those 35 units at $11,037.25.

Bigger returns

The good news is that even bigger returns could be on the cards according to analysts at Macquarie.

A recent note out of the investment bank reveals that its analysts have an outperform rating and $330.00 price target on the company's shares. This suggests that upside of 14.1% is possible over the next 12 months.

If this recommendation proves accurate, those 35 CSL shares would have a market value of $11,550. That's almost $1,500 greater than your original investment.

But it gets better. Macquarie is feeling very positive about the outlook of the CSL Behring business. This is particularly important given how it is far and away the biggest contributor to CSL's overall earnings.

As a result, the broker sees scope for CSL's shares to rise significantly over the next three years thanks to the strength of the CSL Behring business. So much so, it believes that a share price of $500 is possible by 2027.

If that happens, it would mean those 35 shares will be worth a sizeable $17,500. That's a very large increase on the original outlay of $10,123.40.

Here's hoping that Macquarie is on the money with its recommendation and valuation.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Down 50%, why I'd invest $20,000 into CSL shares

A 50% decline in a blue-chip share can signal trouble, but not always a broken story.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »

Retired couple hugging and laughing.
Healthcare Shares

A Budget announcement has put a rocket under this ASX aged care provider's shares

A shake up in the funding model will be a boost for this company.

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

What on earth's going on with Pro Medicus shares?

The quality stock is now driven heavily by expectations.

Read more »

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »